# Deciphera Pharmaceuticals, LLC clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Deciphera Pharmaceuticals, LLC as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Deciphera Pharmaceuticals, LLC: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/deciphera-pharmaceuticals-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 4, 2026 | NCT07744802 | Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants | Deciphera Pharmaceuticals, LLC | Phase 1 | Recruiting | Healthy Male Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744802) |
| April 20, 2026 | NCT07539090 | Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | Healthy Participants | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539090) |
| September 5, 2025 | NCT07158411 | Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | Healthy Participants | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07158411) |
| September 5, 2025 | NCT07158398 | Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07158398) |
| July 20, 2025 | NCT07075471 | MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib | Deciphera Pharmaceuticals, LLC | Observational | Recruiting | Tenosynovial Giant Cell Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07075471) |
| May 11, 2025 | NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Deciphera Pharmaceuticals, LLC | Phase 1 | Recruiting | Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966024) |
| October 8, 2024 | NCT06630234 | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Recruiting | Gastrointestinal Stromal Tumor (GIST) | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06630234) |
| October 1, 2024 | NCT06619561 | A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Deciphera Pharmaceuticals, LLC | Phase 2 | Recruiting | Chronic Graft-Versus-Host Disease (cGVHD) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619561) |
| March 1, 2024 | NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | Deciphera Pharmaceuticals, LLC | Phase 1 | Terminated | Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal... | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06287463) |
| July 24, 2023 | NCT05957367 | A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Active not recruiting | GIST | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05957367) |
| February 17, 2023 | NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | Deciphera Pharmaceuticals, LLC | Phase 3 | Active not recruiting | GIST | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05734105) |
| October 18, 2021 | NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Withdrawn | Gastrointestinal Stromal Tumors | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05080621) |
| September 28, 2021 | NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor | Deciphera Pharmaceuticals, LLC | Phase 3 | Active not recruiting | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant... | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05059262) |
| May 19, 2021 | NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Deciphera Pharmaceuticals, LLC | Phase 1 | Terminated | Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04892017) |
| August 28, 2020 | NCT04530981 | A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with... | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | GIST - Gastrointestinal Stromal Tumor | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04530981) |
| November 1, 2019 | NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | Deciphera Pharmaceuticals, LLC | Not applicable | Approved for marketing | GIST - Gastrointestinal Stromal Tumor | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04148092) |
| October 24, 2018 | NCT03717415 | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Terminated | Locally Advanced or Metastatic Solid Tumor | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03717415) |
| September 17, 2018 | NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Deciphera Pharmaceuticals, LLC | Phase 3 | Active not recruiting | Gastrointestinal Stromal Tumors | 453 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03673501) |
| July 26, 2018 | NCT03601897 | A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Terminated | Locally Advanced or Metastatic Solid Tumor | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03601897) |
| November 27, 2017 | NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies | Deciphera Pharmaceuticals, LLC | Phase 3 | Completed | Gastrointestinal Stromal Tumors | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03353753) |
| March 3, 2017 | NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Deciphera Pharmaceuticals, LLC | Phase 1/2 | Active not recruiting | Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03069469) |
| October 8, 2015 | NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02571036) |
| August 29, 2014 | NCT02228811 | A Study of DCC-2701 in Participants With Advanced Solid Tumors | Deciphera Pharmaceuticals, LLC | Phase 1 | Terminated | Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02228811) |
| January 22, 2009 | NCT00827138 | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | Deciphera Pharmaceuticals, LLC | Phase 1 | Completed | Chronic Myeloid Leukemia | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00827138) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 6 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 7 |
| Recruiting | 5 |
| Active not recruiting | 5 |
| Terminated | 5 |
| Withdrawn | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Gastrointestinal Stromal Tumors | 9 |
| Giant Cell Tumor of Tendon Sheath | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Neoplasm Metastasis | 3 |
| Synovitis, Pigmented Villonodular | 2 |
| Breast Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Melanoma | 2 |
| Endometrial Neoplasms | 1 |
| Carcinosarcoma | 1 |
| Carcinoma, Renal Cell | 1 |
| Carcinoma, Transitional Cell | 1 |
| Mesothelioma | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Mastocytosis, Systemic | 1 |
| Leukemia, Mast-Cell | 1 |
| Mast Cell Activation Disorders | 1 |
| Sarcoma | 1 |
| Neoplasms, Germ Cell and Embryonal | 1 |
| Penile Neoplasms | 1 |
| Renal Insufficiency | 1 |
| Glioma | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Graft vs Host Disease | 1 |
| Immune System Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [B2B medical support companies in the United States](https://specstream.ai/data/businesses/b2b-medical-support-companies/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Truck rental companies in the United States](https://specstream.ai/data/businesses/truck-rental-companies/united-states)
- [Civil rights law firms in the United States](https://specstream.ai/data/businesses/civil-rights-law-firms/united-states)
